ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ VÀ CÁC BIẾN CỐ BẤT LỢI CỦA PHÁC ĐỒ BPAL TRONG ĐIỀU TRỊ LAO TIỀN SIÊU KHÁNG THUỐC TẠI BỆNH VIỆN PHỔI TRUNG ƯƠNG VÀ BỆNH VIỆN PHỔI HÀ NỘI

Abstract

Objective: To evaluate treatment outcomes, adherence to therapy, and adverse events associated with the BPaL regimen in patients with pre-XDR tuberculosis managed at Hanoi Lung Hospital and the National Lung Hospital. Methods: A cross-sectional study with both retrospective and prospective components was conducted on 51 patients with pre-XDR tuberculosis treated with the BPaL regimen at the two hospitals during 2024–2025. Results: The treatment success rate was 92.2%; 84.3% of patients demonstrated good adherence. Adverse events occurred in 58.8% of patients, the majority being mild (grade 1–2); 7.8% experienced grade ≥3 events. The most common adverse events were elevated liver enzymes (29.4%), QTcF prolongation (23.6%), anemia (13.7%), and peripheral neuropathy (11.8%). Conclusion: The BPaL regimen with Linezolid 600 mg/day is safe, effective, and suitable for real-world implementation in Vietnam.